文献速递艾滋病与性传播感染

2018至2023年中国HIV传播性耐药趋势与模式

Trends and Patterns of HIV Transmitted Drug Resistance in China From 2018 to 2023.
PubMed 文献 · J Infect Dis · 2024-01-01

分析2018至2023年中国31省新诊断HIV感染者中传播性耐药(TDR)的流行趋势与模式,共纳入22124例有蛋白酶和逆转录酶序列者,965例(4.36%)存在至少1个TDR突变,总体TDR从2018年4.05%升至2023年5.39%。

要点

  • 22124例中965例(4.36%)携带至少1个TDR突变。
  • NNRTI突变最常见(2.39%),其次NRTI(1.35%)和PI(1.12%)。
  • 总体TDR从2018年4.05%升至2023年5.39%。

核心结论

  • 目前继续使用基于NNRTI的一线抗逆转录病毒治疗方案是合理的。

研究设计与样本

  • 分析2018至2023年中国31省新诊断HIV感染者的人口学、临床和病毒学数据。

主要发现

  • 22124例有蛋白酶和逆转录酶序列的HIV感染者中,965例(4.36%;95%CI 4.1%-4.63%)存在至少1个TDR突变。
  • 最常见的TDR突变为NNRTI突变(2.39%;95%CI 2.19%-2.59%),其次为NRTI突变(1.35%;95%CI 1.2%-1.5%)和PI突变(1.12%;95%CI 0.98%-1.26%)。
  • 总体蛋白酶和逆转录酶TDR从2018年4.05%(95%CI 3.61%-4.52%)升至2023年5.39%(95%CI 4.33%-6.57%)。
  • 4205例中有9例(0.21%;95%CI 0.1%-0.38%)检出低水平整合酶链转移抑制剂TDR。

关键数值与推荐

  • TDR依据世界卫生组织耐药突变监测列表定义。

临床怎么用

  • 作者认为目前继续使用基于NNRTI的一线抗逆转录病毒治疗方案是合理的。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: National treatment guidelines of China evolving necessitates population-level surveillance of transmitted drug resistance (TDR) to inform or update HIV treatment strategies. METHODS: We analyzed the demographic, clinical, and virologic data obtained from people with HIV (PWH) residing in 31 provinces of China who were newly diagnosed between 2018 and 2023. Evidence of TDR was defined by the World Health Organization list for surveillance of drug resistance mutations. RESULTS: Among the 22 124 PWH with protease and reverse transcriptase sequences, 965 (4.36%; 95% CI, 4.1-4.63) had at least 1 TDR mutation. The most frequent TDR mutations were nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.39%; 95% CI, 2.19%-2.59%), followed by nucleoside reverse transcriptase inhibitor mutations(1.35%; 95% CI, 1.2%-1.5%) and protease inhibitor mutations (1.12%; 95% CI, .98%-1.26%). The overall protease and reverse transcriptase TDR increased significantly from 4.05% (95% CI, 3.61%-4.52%) in 2018 to 5.39% (95% CI, 4.33%-6.57%) in 2023. A low level of integrase strand transfer inhibitor TDR was detected in 9 (0.21%; 95% CI, .1%-.38%) of 4205 PWH. CONCLUSIONS: Presently, the continued use of NNRTI-based first-line antiretroviral therapy regimen for HIV treatment has been justified.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ye J, Dong Y, Lan Y, et al. Trends and Patterns of HIV Transmitted Drug Resistance in China From 2018 to 2023. J Infect Dis. 2024. PMID: 39189826. doi:10.1093/infdis/jiae303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。